NEXT GENERATION CONDOM CONTRACEPTION TO TACKLE SEXUALLY TRANSMITTED DISEASES & UNINTENDED PREGNANCIES
RESEARCHER PROFILE (Filmed October 2023)
Dr Simon Cook,
Executive Director, Operations
Eudaemon Technologies
Sydney, Australia
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
Motivated by the potential for significant social impact, Dr. Cook is dedicated to overcoming challenges and driving positive change in global health through his work at Eudaemon Technologies.
The innovative approach at Eudaemon Technologies involves replacing latex with tough hydrogel materials, offering a more skin-like feel with no odour, taste, or allergic reactions. Additionally, these materials have the potential to integrate small molecule drugs, presenting opportunities for enhanced user experience and additional protective measures against STIs.
Beyond his professional endeavours, Dr. Cook enjoys music, particularly playing the guitar, bass guitar, and drums. He also maintains an active lifestyle through sports including soccer and squash.
-
Respiratory health and the microbiome in the lung environment
Dr Taylor leads the Respiratory Health Group within the Microbiome and Host Health Program. His research employs tailored techniques that allow the lung environment to be characterised to a high level of accuracy, including detailed measurements of airway microbiology (microbiome), mucus composition, and inflammation. This information is used to identify predictive markers of chronic lung disease severity as well as determine effective forms of therapy.
-
Causal genes and pathogenic mechanisms underlying gastrointestinal diseases
Professor D’Amato has more than 25 years research experience in the field of human genetics and complex diseases, with activities most recently geared towards a translational application for therapeutic precision in gastroenterology. His team, the Gastrointestinal Genetics Laboratory, combine leading expertise in genomic, computational and pre-clinical research, and have contributed important breakthroughs linking specific genes and pathogenetic mechanisms to a number of gastrointestinal diseases like inflammatory bowel disease (IBD), microscopic colitis (MC) and irritable bowel syndrome (IBS).
-
Nutraceutical and pharmacological intervention in neurological disorders
Dr Virginie Lam is a neuroscientist and cerebrovascular biologist with over 15 years of research experience, including more than seven years post-PhD. She co-leads the Neurovascular and Metabolic Diseases Laboratory at the Curtin Medical Research Institute and holds an affiliate appointment at the Perron Institute for Neurological and Translational Science. Her research focuses on the interface between neurovascular health, cognitive function, and therapeutic translation in neurodegenerative disorders.
